Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Enrolment complete for venous leg ulcer healing product

This article was originally published in Clinica

Executive Summary

New York firm Ortec International has completed patient enrolment for its confirmatory trial for the use of cryopreserved OrCel - a regenerative product for chronic wounds - to treat venous leg ulcers. The firm hopes to validate results from its pivotal trial, where 59% of patients treated with cryopreserved OrCel achieved wound closure, compared with 36% of patients receiving standard care. OrCel is composed of a collagen sponge containing cells that secrete growth factors and cytokines normally found in acute wounds. Ortec hopes to submit a PMA application to the FDA by mid July 2006, after the 12-week treatment phase is completed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT051520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel